Press Releases Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 November 11, 2011 Summary ToggleMultiple Programs from Merrimack Pharmaceuticals’ Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11, 2011 Summary ToggleMerrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients August 1, 2011 Summary ToggleFDA Grants Orphan Drug Status to Merrimack Pharmaceuticals’ MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer June 30, 2011 Summary ToggleMerrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer May 24, 2011 Summary ToggleMultiple Programs from Merrimack Pharmaceuticals’ Pipeline to be Presented at the 2011 ASCO Annual Meeting Phase 2 data to be presented on MM-398, a novel liposomal formulation of irinotecan, in gemcitabine-refractory pancreatic cancer patients May 9, 2011 Summary ToggleMerrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan Reuniting the worldwide rights allows for a broad, global development program for MM-398 April 20, 2011 Summary ToggleMerrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients Merrimack investigating whether MM-111 can safely be added to standard therapies used to treat both conventional HER2 positive breast cancers and other HER2 positive solid tumors. April 13, 2011 Summary ToggleMerrimack Pharmaceuticals Raises $77 Million in Private Financing Funds provide resources to advance Merrimack's pipeline of novel cancer therapeutics April 5, 2011 Summary TogglePhase 1 Data on MM-121 Will Be Presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) MM-121 as a single agent in a First in Human Phase 1 dose escalation study April 1, 2011 Summary ToggleMerrimack to Present Pre-Clinical Data on MM-111 and MM-302 at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) MM-111 in pre-clinical combinations with lapatinib and endocrine therapies. MM-302 in pre-clinical studies explaining its mechanism of action Pagination First page First Previous page Previous … Page 26 Current page 27 Page 28 Page 29 Next page Next Last page Last